Traders should monitor near-term sales uptake and gross margin trends, as limited-competition generics typically offer strong profitability. This approval adds to ANI’s track record of successful ANDA approvals and may support valuation re-rating if commercial execution continues.
ANIP drugs
ANIP drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 8 $79.01entry
- T+1 · 8mo ago +1.43%α +0.86% · $80.14
- T+5 · 7mo ago −3.20%α −6.72% · $76.48
- T+20 · 7mo ago +7.11%α −1.43% · $84.63
- T+60 · 5mo ago +8.88%α −1.57% · $86.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ANI Pharmaceuticals announced FDA approval and immediate launch of Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg, the generic version of Monoket®, reinforcing its generics pipeline and R&D execution. The product targets a limited-competition market, supporting near-term revenue diversification.
Key Facts
- FDA approved ANI's Abbreviated New Drug Application (ANDA) for Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg.
- Product launched immediately as a generic version of Monoket®.
- Indication is for cardiovascular conditions, with limited competition expected.
- Strengthens ANI’s Generics business and R&D track record.
Financial Impact
Moderate revenue contribution expected; exact sales figures not disclosed but positioned as part of steady product launch cadence.
Risk Factors
- Uncertainty around market adoption and competition despite 'limited-competition' claim.
- Supply chain or manufacturing delays could hinder revenue realization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269952 |
Track record
34 reports on ANIP
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +7.08% at T+60 after the Jul 16, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers